Regulatory Intelligence
and Research

Eleven months after filing its first submission to the Rwanda Food and Drugs Authority, THESYL reached a significant operational milestone: on 17 June 2025, the 31st product dossier was submitted to Rwanda FDA on behalf of USOPHARMA Ltd, marking the completion of more than half of the 50-product registration programme initiated in July 2024.

The 31 submissions span two distinct product categories. The first is conventional small-molecule medicines, covering oral solid forms — tablets, capsules, and powders for oral suspension — as well as inhalation products. The second is biologicals and biosimilars, including lyophilised powders for injection, among them gonadotropins and a recombinant growth hormone. Products originate from manufacturers across multiple countries, and the therapeutic breadth of the portfolio is considerable: respiratory disease, cardiovascular conditions, CNS and neurological disorders, anti-infective treatment, pain and inflammation, metabolic and endocrine conditions, reproductive health, musculoskeletal health, and psychiatry.

Important to note: all 31 submissions are made on behalf of USOPHARMA Ltd as the Marketing Authorization Holder. These are not THESYL's own products. THESYL's role is that of a regulatory affairs partner — responsible for dossier preparation, Rwanda-specific documentation adaptation, submission management, and ongoing regulatory follow-up throughout the Rwanda FDA review process.

Reaching 31 submissions within eleven months reflects the operational capacity THESYL has built since establishing its Rwanda presence, and the complexity of managing a portfolio of this scale — each product requiring its own documentation package, manufacturer-specific GMP verification, and country-specific Certificate of Pharmaceutical Product. The remaining submissions from the 50-product programme continue to progress through preparation and are scheduled for filing in the coming months.

On 2 July 2024, THESYL submitted its first dossier to the Rwanda Food and Drugs Authority (Rwanda FDA) on behalf of USOPHARMA Ltd, a Kigali-based pharmaceutical distribution company. This submission marked the beginning of a structured 50-product registration programme — one of the most ambitious product registration mandates undertaken by a CRO operating in Rwanda at the time.

The programme covers a deliberately broad portfolio sourced from manufacturers across multiple countries: conventional small-molecule medicines in oral solid, oral liquid, and inhalation forms, as well as biologicals and biosimilars administered as lyophilised powders for injection. Therapeutically, the portfolio spans respiratory disease, cardiovascular conditions, CNS and neurological disorders, anti-infective treatment, pain management, metabolic and endocrine conditions, reproductive health, and musculoskeletal health.

All registrations are filed on behalf of USOPHARMA Ltd as Marketing Authorization Holder — THESYL acts as the regulatory affairs partner managing the full dossier lifecycle from gap analysis and preparation through to submission, follow-up, and post-registration compliance.

"We have been collaborating with THESYL on drug market registration projects, and their expertise has been instrumental in navigating every step. Their regulatory services have proven essential, and we look forward to expanding our partnership to include upcoming pharmacovigilance initiatives."

Placide Sophroni UWINGENEYE, Managing Director, USOPHARMA Ltd

The commencement of this programme established THESYL's footprint in Rwanda and set the foundation for what would become a growing pipeline of Rwanda FDA submissions across the following months.

The assumption that leads to most delays

International manufacturers - particularly those based in Europe or India - approach Rwanda FDA registration with one of two incorrect assumptions: that the process mirrors a simplified version of EMA requirements, or that it is informal enough to be managed reactively. Both lead to the same outcome: significant delays, repeated deficiency rounds, and inflated costs. Rwanda FDA achieved WHO Maturity Level 3 in December 2024, confirming a stable, well-functioning regulatory system that conducts rigorous, structured technical reviews.

Error 1: Submitting dossiers without Rwanda-specific Module 1 adaptation

Rwanda FDA has its own administrative requirements for Module 1. A dossier prepared for EMA, SAHPRA, or any other authority cannot be submitted as-is. Application forms, product labelling, the Summary of Product Characteristics, and the product information leaflet must conform to Rwanda FDA formats and templates. Failure to adapt Module 1 is the single most common cause of administrative rejection before technical review even begins.

Error 2: Not understanding GMP recognition

Manufacturers holding a current EU GMP certificate, US FDA GMP clearance, or WHO GMP certification benefit from a streamlined GMP assessment pathway and eligibility for the Abridged Procedure. Rwanda FDA also recognises GMP decisions from Ghana FDA and Tanzania TMDA. Manufacturers from non-recognised authorities face a more demanding verification process, longer timelines, and higher registration fees - all avoidable with prior planning.

Error 3: Choosing the wrong registration pathway

Rwanda FDA offers three procedural pathways - Abridged, National Full Assessment, and Mutual Recognition. Choosing incorrectly can cost many months. The Abridged Procedure applies to products approved by a recognised SRA or qualifying African NRA. The National Full Assessment requires a complete CTD dossier where no reference approval exists. The Mutual Recognition Procedure is the fastest pathway for manufacturers already registered in a recognised African market.

Error 4: Missing the CPP requirement

Rwanda FDA requires a Certificate of Pharmaceutical Product (CPP) from the country of manufacture that specifically names Rwanda as the importing country. A generic multi-country CPP is not accepted. Obtaining a Rwanda-specific CPP frequently takes 3-6 months and sits on the critical path of every submission.

Error 5: Underestimating stability data requirements

Rwanda sits in ICH climatic Zone IVb (40C / 75% RH) - the most challenging stability testing conditions. Stability data generated under Zone II or IVa conditions alone will generate a major deficiency query. Manufacturers must commission Zone IVb studies before submission - a minimum of six months of real-time data.

Error 6: Overlooking the registration fee differential

This differential is a deliberate regulatory policy incentive designed to attract high-quality products with established regulatory pedigrees. It should be factored into market entry cost planning from the outset. Manufacturers from non-SRA countries may qualify for the lower fee tier if their product holds valid WHO Prequalification or the manufacturing facility holds GMP certification from a recognised authority.

What a well-prepared submission looks like

Manufacturers who complete Rwanda FDA registration without major delays typically invest 3-4 months in pre-submission preparation: verifying GMP status, initiating CPP requests early, confirming pathway eligibility, commissioning Zone IVb stability studies, adapting Module 1 documents, and establishing a local technical representative arrangement. Review timelines - once a complete submission is lodged - are typically 9-15 months under the Abridged Procedure and 15-24 months under National Full Assessment.

Why the pathway decision matters more than the dossier

In pharmaceutical registration, manufacturers naturally focus on the dossier. In the Rwanda FDA context, however, the single decision with the greatest impact on timeline, cost, and likelihood of success is often made before a single page of the dossier is prepared: the choice of registration pathway.

Pathway 1: The Abridged Procedure

Available for products approved by a recognised Stringent Regulatory Authority - EMA, US FDA, Health Canada, TGA Australia, Japan PMDA, or WHO Prequalification. Rwanda FDA conducts a risk-based assessment relying substantially on the reference SRA's evaluation, requiring Rwanda-specific Module 1 documentation and confirmatory data rather than a full CTD submission. Typical review timeline: 9-15 months. Registration fee: USD 750. This is the fastest pathway and almost always the correct choice for manufacturers with existing SRA approvals.

Pathway 2: The National Full Assessment

Required for products without a recognised SRA approval - most commonly generics and biosimilars from non-SRA countries. Rwanda FDA conducts a complete independent technical review of quality, safety, and efficacy. For biosimilar products, a full comparability package against the Reference Biological Product (RBP) is required. Typical review timeline: 15-24+ months. Registration fee: USD 2,000. Despite these demands, this pathway is appropriate and necessary for a significant proportion of the generic and biosimilar portfolio that serves the Rwandan market.

Pathway 3: The Mutual Recognition Procedure

Rwanda FDA has established mutual recognition arrangements with qualifying African NRAs, including Ghana FDA (MoU signed 2022), and participates in EAC joint assessment frameworks. Where a product is already registered in a qualifying African reference market, the MRP allows Rwanda FDA to rely on the reference authority's assessment - the fastest and lowest-burden pathway available. Rwanda FDA's WHO Maturity Level 3 achievement means its own assessments are increasingly relied upon by other African NRAs in the reverse direction - creating opportunities for manufacturers who register in Rwanda first to use it as a regional springboard.

The decision framework

• Does the product hold a current marketing authorisation from a recognised SRA? - Abridged Procedure
• Is the product registered in a country with which Rwanda FDA has a mutual recognition arrangement? - Assess MRP eligibility
• Does the manufacturer hold GMP certification from a recognised authority? - Determines fee tier and GMP assessment pathway
• None of the above? - National Full Assessment with full CTD preparation

A continent-sized research gap

Non-communicable diseases - cardiovascular disease, type 2 diabetes, cancer, COPD, and metabolic disorders - now account for the majority of premature deaths in sub-Saharan Africa. Yet fewer than 3% of registered global Phase II-IV trials include African sites, and of those that do, the vast majority target HIV, malaria, and tuberculosis. The consequence is a growing treatment gap: therapies developed and trialled in Western or East Asian populations, then applied to African patients whose genetic profiles, comorbidity burdens, and treatment access patterns may differ in clinically meaningful ways.

Why Rwanda specifically

• Regulatory infrastructure: Rwanda FDA achieved WHO Maturity Level 3 in December 2024 - one of only eight African countries to hold this designation - confirming a stable, well-functioning regulatory system capable of rigorous clinical trial application review.
• Patient population access: Rwanda's relatively concentrated urban population, with healthcare that funnels patients through a limited number of tertiary and district facilities, creates meaningful site efficiency for trial recruitment in Kigali and secondary cities.
• Operational environment: Political stability, consistent government healthcare investment, English-French bilingualism, and a growing GCP-trained research workforce reduce the operational friction characteristic of many African trial settings.
• Cost efficiency: Trial execution costs in Rwanda are materially lower than in South Africa or Kenya without a proportionate quality compromise - site costs, investigator fees, patient stipends, and monitoring costs are all lower.
• Genetic diversity: Rwanda's patient population offers access to ancestral genetic backgrounds underrepresented in global clinical trial databases - directly relevant to oncology, rare disease, and pharmacogenomics research.

What sponsors need to plan for

Clinical trial initiation in Rwanda requires parallel submissions to Rwanda FDA (as competent authority) and the Rwanda National Ethics Committee (RNEC). Site selection is the most critical operational decision: Rwanda has a limited number of sites with documented GCP experience in NCD therapeutic areas, and a rigorous feasibility assessment before site commitment is essential. Hybrid and decentralized trial models - including eConsent and remote monitoring - are increasingly viable given smartphone penetration in urban Rwanda.

Rwanda should be on the shortlist of every sponsor conducting Phase II-IV trials in cardiovascular, metabolic, oncological, or respiratory indications seeking African site inclusion.

The shift that is already happening

Pharmacovigilance expectations across East Africa have shifted materially over the past three years. Rwanda FDA, Kenya PPB, Tanzania TMDA, and Uganda NDA are all moving - at different speeds - toward requirements that increasingly reflect ICH E2A and E2B principles: expedited reporting for serious unexpected adverse reactions, structured periodic safety reporting, designated local PV contacts with genuine competence, and active post-marketing surveillance. Rwanda FDA, having achieved WHO Maturity Level 3 in December 2024, now has the regulatory capacity to identify and act on PV compliance deficiencies during renewals, inspections, and variation assessments.

What Rwanda FDA expects from MAHs

• A designated local pharmacovigilance contact - a person with PV training who can receive adverse event reports, exercise judgment on seriousness and causality, and communicate with Rwanda FDA on safety matters
• A documented ICSR collection pathway - a mechanism by which adverse events from Rwandan healthcare providers, pharmacists, and patients actually reach the MAH's safety database
• MedDRA coding competence and a validated safety database
• Periodic Safety Update Reports aligned to Rwanda FDA's submission calendar
• A Pharmacovigilance System Master File that accurately describes the local pharmacovigilance system, not merely the global system with a local addendum

The critical gap: the local blind spot

The most consistent deficiency in MAH pharmacovigilance arrangements for East African-registered products is the local blind spot: the global safety database is functional and compliant, but it never captures adverse events actually occurring in the local patient population - because those events are reported through informal channels that the MAH's global system cannot see. In practice: a patient in Kigali experiences an adverse reaction, tells her pharmacist, who files with Rwanda FDA's national PV system. Rwanda FDA receives the report. The MAH receives nothing.

An active local PV presence closes that loop: maintaining relationships with healthcare providers and pharmacists, conducting ICSR reporting training, actively monitoring the Rwanda FDA pharmacovigilance database, and ensuring every captured signal reaches the MAH's global safety team within the applicable regulatory timeframe.

The cost of inaction

MAHs who treat East African pharmacovigilance as a passive compliance checkbox are building a growing regulatory liability. As Rwanda FDA and its peers increase inspection activity, PV compliance deficiencies are increasingly surfacing during renewal assessments - with registration suspension as a potential outcome. The cost of building a proper local PV system is a fraction of the cost of a registration at risk.

A new continental regulator - headquartered in Kigali

The AMA Treaty was adopted by the African Union Assembly in February 2019 and entered into force in November 2021 following ratification by fifteen AU member states. Its headquarters in Kigali places it directly adjacent to Rwanda FDA, one of the continent's most advanced national regulatory authorities, and at the centre of East Africa's emerging regulatory infrastructure.

What the AMA is - and what it is not

The AMA is not replacing national regulatory authorities. Products must still be registered nationally to be marketed in each African country. What the AMA provides is a continental coordination layer: harmonised standards, joint regulatory reviews for priority products, scientific opinions that national NRAs can draw upon, regulatory intelligence and data sharing across NRAs, and capacity support for less developed regulatory systems.

The AMA's core functions

• Joint regulatory reviews: The AMA can conduct joint assessments of medicines - particularly vaccines, biologicals, and priority health products - that national NRAs can use to accelerate their own registration decisions. A manufacturer securing a positive AMA scientific opinion gains a significant advantage in multi-country African registration programmes.
• Regulatory harmonisation: The AMA coordinates harmonisation across Africa, building on the AMRH initiative and regional schemes like ZAZIBONA and the EAC joint assessment framework. Over time, this should reduce the divergence between national requirements that currently forces manufacturers to prepare country-specific dossiers for each African market.
• Pharmacovigilance coordination: The AMA has a continental pharmacovigilance mandate - coordinating adverse event data sharing across African NRAs and building pan-African safety signal detection capability.

What this means for manufacturers and MAHs

In the near term - the next two to three years - the AMA's practical impact on individual product registration decisions will be limited. The institution is still in its operationalisation phase. In the medium term - three to seven years - the AMA's joint review pathway will become increasingly relevant for sponsors with large pan-African portfolios. Manufacturers planning African market entry now should structure their programmes to be AMA-ready: harmonised CTD dossiers, robust pharmacovigilance systems, and GMP standards that meet recognised authority benchmarks.

The Kigali advantage

Rwanda's combination of a mature, ML3-certified national regulatory authority and the AMA headquarters makes Kigali an increasingly important regulatory centre of gravity in Africa - one that rewards early, high-quality regulatory engagement.

The pace of change has accelerated

Five years ago, the dominant narrative about African pharmaceutical regulation was one of fragmentation, capacity constraints, and unpredictable timelines. That narrative is increasingly out of date. A combination of institutional development, continental harmonisation initiatives, and deliberate government investment has produced a regulatory landscape that is changing faster than most manufacturers' market access strategies have kept pace with.

The WHO Maturity Level milestone: what ML3 means in practice

WHO Maturity Level 3 - achieved by Rwanda FDA in December 2024, and held by eight African NRAs including Ghana, Tanzania, Nigeria, South Africa, Egypt, Zimbabwe, and Senegal - signifies a stable, well-functioning, and integrated regulatory system. It confirms that the NRA conducts rigorous, consistent assessments; maintains a functioning quality management system; and makes regulatory decisions that other countries can rely upon. For manufacturers, this means real technical reviews, substantive GMP inspections, specific deficiency queries, and active post-registration surveillance. ML3 also enables mutual recognition flows in both directions - creating genuine efficiencies for manufacturers who plan registration programmes around ML3 anchor markets.

The African Medicines Agency: a new continental architecture

The AMA, headquartered in Kigali since 2023, represents the most structurally significant development in African pharmaceutical regulation in a generation. While still in its operationalisation phase, the AMA is building the framework for continental joint regulatory reviews, harmonised standards, and coordinated pharmacovigilance. Manufacturers with multi-country African portfolios should monitor AMA developments closely and structure their dossiers and PV systems to be AMA-compatible as requirements emerge.

EAC harmonisation: real progress, real implications

Within the East African Community, the EAC Joint Assessment framework allows member state NRAs to conduct collaborative assessments with outputs recognised across participating countries. Rwanda FDA has domesticated the EAC Abridged Procedure framework. A product assessed positively under EAC joint assessment creates accelerated registration pathways in Rwanda, Uganda, Tanzania, Kenya, and Burundi simultaneously - the most immediately practical harmonisation mechanism available to manufacturers.

The strategic response

Manufacturers and MAHs who are ahead of this curve treat African regulatory compliance as a strategic function rather than an administrative one, invest in in-country regulatory intelligence rather than relying on generic market entry reports, and build pharmacovigilance and regulatory affairs infrastructure in African markets proactively. The direction of travel is clear, the pace is real, and the manufacturers who engage seriously now will find the competitive landscape considerably more favourable than those who wait.